Compare FOXX & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOXX | AKTX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 17.2M |
| IPO Year | N/A | N/A |
| Metric | FOXX | AKTX |
|---|---|---|
| Price | $4.57 | $0.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | ★ 2.7M | 464.5K |
| Earning Date | 11-18-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $63,030,415.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 139.29 | N/A |
| 52 Week Low | $1.71 | $0.42 |
| 52 Week High | $11.00 | $1.73 |
| Indicator | FOXX | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.39 | 37.17 |
| Support Level | $1.71 | $0.42 |
| Resistance Level | $6.90 | $0.50 |
| Average True Range (ATR) | 0.89 | 0.06 |
| MACD | 0.28 | 0.00 |
| Stochastic Oscillator | 54.12 | 29.62 |
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.